Asthma-like features and clinical course of chronic obstructive pulmonary disease: An analysis from the hokkaido COPD cohort study

American Journal of Respiratory and Critical Care Medicine

Volumn 194, Issue 11, 2016, Pages 1358-1365

  Suzuki, Masaru ^a   Makita, Hironi ^a   Konno, Satoshi ^a   Shimizu, Kaoruko ^a   Kimura, Hiroki ^a   Kimura, Hirokazu ^a   Nishimura, Masaharu ^a  

^a HOKKAIDO UNIVERSITY   (Japan)

Author keywords

Asthma COPD overlap syndrome; Atopy; Blood eosinophilia; Bronchodilator reversibility

Indexed keywords

AGED; ARTICLE; ASTHMA; ATOPY; BODY MASS; CHEST TIGHTNESS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL FEATURE; COHORT ANALYSIS; COUGHING; DISEASE COURSE; DISEASE EXACERBATION; DYSPNEA; EOSINOPHIL COUNT; EOSINOPHILIA; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; MORTALITY RATE; PRIORITY JOURNAL; ST. GEORGE RESPIRATORY QUESTIONNAIRE; WHEEZING; BLOOD; CLINICAL TRIAL; COMPLICATION; FOLLOW UP; JAPAN; MULTICENTER STUDY; PATHOPHYSIOLOGY; PHYSIOLOGY; SYNDROME;

AGED; ASTHMA; COHORT STUDIES; EOSINOPHILIA; FEMALE; FOLLOW-UP STUDIES; FORCED EXPIRATORY VOLUME; HUMANS; JAPAN; MALE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SYNDROME;

EID: 85002992405     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201602-0353OC     Document Type: Article

References (35)

1. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease [updated 2015; accessed 2015 Nov. 18]. Available from: http://www.goldcopd.org
2. Global Initiative for Asthma; Global Initiative for Chronic Obstructive Lung Disease. 2015 Asthma, COPD and asthma-COPD overlap syndrome (ACOS) [updated 2015; accessed 2015 Nov. 18]. Available from: http://www.ginasthma.org
3. Hardin M, Silverman EK, Barr RG, Hansel NN, Schroeder JD, Make BJ, Crapo JD, Hersh CP; COPDGene Investigators. The clinical features of the overlap between COPD and asthma. Respir Res 2011;12:127.
4. Bateman ED, Reddel HK, Van Zyl-Smit RN, Agusti A. The asthma-COPD overlap syndrome: towards a revised taxonomy of chronic airways diseases? Lancet Respir Med 2015;3:719-728.
5. Tho NV, Park HY, Nakano Y. Asthma-COPD overlap syndrome (ACOS): a diagnostic challenge. Respirology 2016;21:410-418.
6. Marsh SE, Travers J, Weatherall M, Williams MV, Aldington S, Shirtcliffe PM, Hansell AL, Nowitz MR, McNaughton AA, Soriano JB, et al. Proportional classifications of COPD phenotypes. Thorax 2008;63:761-767.
7. Soler-Cataluña JJ, Cosío B, Izquierdo JL, López-Campos JL, Marín JM, Agüero R, Baloira A, Carrizo S, Esteban C, Galdiz JB, et al. Consensus document on the overlap phenotype COPD-asthma in COPD. Arch Bronconeumol 2012;48:331-337.
8. Golpe R, Pérez De Llano L. Are the diagnostic criteria for asthma-COPD overlap syndrome appropriate in biomass smoke-induced chronic obstructive pulmonary disease? Arch Bronconeumol 2016;52:110.
9. Cosio BG, Soriano JB, Ĺopez-Campos JL, Calle-Rubio M, Soler-Cataluna JJ, De-Torres JP, Marín JM, Martínez-Gonzalez C, De Lucas P, Mir I, et al.; CHAIN Study. Defining the asthma-COPD overlap syndrome in a COPD cohort. Chest 2016;149:45-52.
10. Makita H, Nasuhara Y, Nagai K, Ito Y, Hasegawa M, Betsuyaku T, Onodera Y, Hizawa N, Nishimura M; Hokkaido COPD Cohort Study Group. Characterisation of phenotypes based on severity of emphysema in chronic obstructive pulmonary disease. Thorax 2007;62:932-937.
11. Nishimura M, Makita H, Nagai K, Konno S, Nasuhara Y, Hasegawa M, Shimizu K, Betsuyaku T, Ito YM, Fuke S, et al.; Hokkaido COPD Cohort Study Investigators. Annual change in pulmonary function and clinical phenotype in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2012;185:44-52.
12. Suzuki M, Makita H, Ito YM, Nagai K, Konno S, Nishimura M; Hokkaido COPD Cohort Study Investigators. Clinical features and determinants of COPD exacerbation in the Hokkaido COPD cohort study. Eur Respir J 2014;43:1289-1297.
13. Global Initiative for Asthma. Global strategy for asthma management and prevention [updated 2015; accessed 2015 Nov. 18]. Available from: http://www.ginasthma.org
14. Goddard PR, Nicholson EM, Laszlo G, Watt I. Computed tomography in pulmonary emphysema. Clin Radiol 1982;33:379-387.
15. Maeda Y, Hizawa N, Takahashi D, Fukui Y, Konno S, Nishimura M. Genetic impact of functional single nucleotide polymorphisms in the 39-UTR region of the chemoattractant receptor expressed on Th2 cells (CRTH2) gene on asthma and atopy in a Japanese population. Int Arch Allergy Immunol 2007;142:51-58.
16. Miravitlles M, Soriano JB, Ancochea J, Muñoz L, Duran-Tauleria E, Śanchez G, Sobradillo V, García-Río F. Characterisation of the overlap COPD-asthma phenotype: focus on physical activity and health status. Respir Med 2013;107:1053-1060.
17. Hardin M, Cho M, McDonald ML, Beaty T, Ramsdell J, Bhatt S, Van Beek EJ, Make BJ, Crapo JD, Silverman EK, et al. The clinical and genetic features of COPD-asthma overlap syndrome. Eur Respir J 2014;44:341-350.
18. Menezes AM, Montes De Oca M, Pérez-Padilla R, Nadeau G, Wehrmeister FC, Lopez-Varela MV, Muiño A, Jardim JR, Valdivia G, Tálamo C; PLATINO Team. Increased risk of exacerbation and hospitalization in subjects with an overlap phenotype: COPDasthma. Chest 2014;145:297-304.
19. Kauppi P, Kupiainen H, Lindqvist A, Tammilehto L, Kilpeläinen M, Kinnula VL, Haahtela T, Laitinen T. Overlap syndrome of asthma and COPD predicts low quality of life. J Asthma 2011;48:279-285.
20. Hanania NA, Sharafkhaneh A, Celli B, Decramer M, Lystig T, Kesten S, Tashkin D. Acute bronchodilator responsiveness and health outcomes in COPD patients in the UPLIFT trial. Respir Res 2011;12:6.
21. Marín JM, Ciudad M, Moya V, Carrizo S, Bello S, Piras B, Celli BR, Miravitlles M. Airflow reversibility and long-term outcomes in patients with COPD without comorbidities. Respir Med 2014;108:1180-1188.
22. Pizzichini E, Pizzichini MM, Gibson P, Parameswaran K, Gleich GJ, Berman L, Dolovich J, Hargreave FE. Sputum eosinophilia predicts benefit from prednisone in smokers with chronic obstructive bronchitis. Am J Respir Crit Care Med 1998;158:1511-1517.
23. Brightling CE, Monteiro W, Ward R, Parker D, Morgan MD, Wardlaw AJ, Pavord ID. Sputum eosinophilia and short-term response to prednisolone in chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2000;356:1480-1485.
24. Brightling CE, McKenna S, Hargadon B, Birring S, Green R, Siva R, Berry M, Parker D, Monteiro W, Pavord ID, et al. Sputum eosinophilia and the short term response to inhaled mometasone in chronic obstructive pulmonary disease. Thorax 2005;60:193-198.
25. Leigh R, Pizzichini MM, Morris MM, Maltais F, Hargreave FE, Pizzichini E. Stable COPD: predicting benefit from high-dose inhaled corticosteroid treatment. Eur Respir J 2006;27:964-971.
26. Fattahi F, Ten Hacken NH, Löfdahl CG, Hylkema MN, Timens W, Postma DS, Vonk JM. Atopy is a risk factor for respiratory symptoms in COPD patients: results from the EUROSCOP study. Respir Res 2013;14:10.
27. Pascoe S, Locantore N, Dransfield MT, Barnes NC, Pavord ID. Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials. Lancet Respir Med 2015;3:435-442.
28. Watz H, Tetzlaff K, Wouters EF, Kirsten A, Magnussen H, Rodriguez-Roisin R, Vogelmeier C, Fabbri LM, Chanez P, Dahl R, et al. Blood eosinophil count and exacerbations in severe chronic obstructive pulmonary disease after withdrawal of inhaled corticosteroids: a post-hoc analysis of the WISDOM trial. Lancet Respir Med 2016;4:390-398.
29. Barnes NC, Sharma R, Lettis S, Calverley PM. Blood eosinophils as a marker of response to inhaled corticosteroids in COPD. Eur Respir J 2016;47:1374-1382.
30. 1. Am J Respir Crit Care Med 1995;151:1377-1382.
31. Postma DS, De Vries K, Koëter GH, Sluiter HJ. Independent influence of reversibility of air-flow obstruction and nonspecific hyperreactivity on the long-term course of lung function in chronic air-flow obstruction. Am Rev Respir Dis 1986;134:276-280.
32. Tashkin DP, Altose MD, Connett JE, Kanner RE, Lee WW, Wise RA; The Lung Health Study Research Group. Methacholine reactivity predicts changes in lung function over time in smokers with early chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1996;153:1802-1811.
33. Lapperre TS, Snoeck-Stroband JB, Gosman MM, Jansen DF, Van Schadewijk A, Thiadens HA, Vonk JM, Boezen HM, Ten Hacken NH, Sont JK, et al.; Groningen Leiden Universities Corticosteroids in Obstructive Lung Disease Study Group. Effect of fluticasone with and without salmeterol on pulmonary outcomes in chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med 2009;151:517-527.
34. Bafadhel M, McKenna S, Terry S, Mistry V, Reid C, Haldar P, McCormick M, Haldar K, Kebadze T, Duvoix A, et al. Acute exacerbations of chronic obstructive pulmonary disease: identification of biologic clusters and their biomarkers. Am J Respir Crit Care Med 2011;184:662-671.
35. Fukuchi Y, Fernandez L, Kuo HP, Mahayiddin A, Celli B, Decramer M, Kesten S, Liu D, Tashkin D. Efficacy of tiotropium in COPD patients from Asia: a subgroup analysis from the UPLIFT trial. Respirology 2011;16:825-835.